Immune checkpoint inhibitors enhance cytotoxicity of cytokine-induced killer cells against human myeloid leukaemic blasts. - Wikidata - awgldk - TriplyDB

Immune checkpoint inhibitors enhance cytotoxicity of cytokine-induced killer cells against human myeloid leukaemic blasts.

Immune checkpoint inhibitors enhance cytotoxicity of cytokine-induced killer cells against human myeloid leukaemic blasts.

http://www.wikidata.org/entity/Q38787535

about

Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy.Programmed cell death-1 pathway inhibition in myeloid malignancies: implications for myeloproliferative neoplasms.Cell-based immunotherapy with cytokine-induced killer (CIK) cells: From preparation and testing to clinical application.Mesenchymal Stem Cells in Myeloid Malignancies: A Focus on Immune Escaping and Therapeutic Implications.Checkpoint blockade in solid tumors and B-cell malignancies, with special consideration of the role of CD200.The progress and current status of immunotherapy in acute myeloid leukemia.Safety and activity of PD-1 blockade-activated DC-CIK cells in patients with advanced solid tumors.Influence of different ex vivo cell culture methods on the proliferation and anti-tumor activity of cytokine-induced killer cells from gastric cancer patients.Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy

P2860

Q33875615-8C11EB28-82E9-497C-842F-8714E22B7007 Q39072004-8AEF50DE-C415-4754-8C5F-85CC3096F04F Q40289330-D8126ACA-5168-4784-BDB0-7DCA82070800 Q41695046-24032740-4159-4A3D-A296-DE9751771E14 Q46971015-C0FB2D26-7467-4AAF-9AA1-9641D65A6745 Q47590707-34DA7A7E-424C-4EBC-B1AE-AC0F2326318E Q52597541-77BFFAE8-FDAC-406A-98C9-6F5B4074D4F4 Q55034487-7BB7D079-4B1C-4C9D-847A-C460089286AF Q58566155-F65CD3A7-9ECD-4B58-9325-784869D3C277

P2860

Immune checkpoint inhibitors enhance cytotoxicity of cytokine-induced killer cells against human myeloid leukaemic blasts.

http://www.wikidata.org/entity/Q38787535

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Immune checkpoint inhibitors e ...... uman myeloid leukaemic blasts.

@en

type

label

Immune checkpoint inhibitors e ...... uman myeloid leukaemic blasts.

@en

prefLabel

Immune checkpoint inhibitors e ...... uman myeloid leukaemic blasts.

@en

P1433

Q38787535-69B00316-3A54-4FEF-BC8D-B78D12685460

P1476

Q38787535-F30AD0BE-E315-4F42-8063-AF8012A9DFD9

P2093

Q38787535-4B270A70-417A-4BEA-94DF-C06A14500B0D

Q38787535-BCAA7BB1-28FE-4127-BBBE-E6B860088ED7

P2860

Q38787535-087FD59B-CE37-4FE6-8A78-42A695CD89F0

Q38787535-08EA3D60-26D0-4B4A-AC4B-D90124DB3DD5

Q38787535-1FEF82D6-90D8-4BF1-A345-7CF32DEB6AAD

Q38787535-22AA1BBE-69CD-4205-AD62-9716697E0A42

Q38787535-232E3406-0F90-43D3-B24C-55A8715E51F2

Q38787535-2CEA9826-38B0-4AC0-99FE-86DF4D6880A9

Q38787535-2D6D58CC-D12B-4F03-B0B9-8B33756B8D00

Q38787535-2FA8D885-6123-488C-888F-40C042515BFF

Q38787535-2FCCC71D-18ED-4CE8-A3E4-F406129CC791

Q38787535-429B375A-0EF5-4FF5-BEBF-9C970AA4969F

P2888

Q38787535-66BF6899-3E84-4C3B-99BD-4AA72F19B3B4

P304

Q38787535-0D611D38-73C3-441F-BEC4-6AD9A870FB01

P31

Q38787535-A3402F30-CC21-433C-A3E4-F468F978FF49

P356

Q38787535-25EB82B1-A864-4B1A-9322-3FF01D421186

P433

Q38787535-9F1A209F-BD34-4DEA-A1A8-B40D46F85542

P478

Q38787535-EFCFDF95-6AFA-419C-92FF-E144784F9B20

P50

Q38787535-17AE680F-EAA9-4C44-8169-17341338F478

Q38787535-97C7BECC-7E19-4FCF-99FC-1E62D08C26BB

P577

Q38787535-89C45173-BA70-4490-B914-62F846B9922E

P6179

Q38787535-F4996848-5008-4ADE-9AB4-44A2C082C949

P698

Q38787535-E743D92D-62ED-4396-B1CF-44A07930D60C

P921

Q38787535-2D2258BE-DA91-4336-9C86-E32432B9EED7

P356

S00262-016-1815-8

P1433

Cancer Immunology, Immunotherapy

P1476

Immune checkpoint inhibitors e ...... human myeloid leukaemic blasts

@en

P2093

Su Li Poh

http://www.w3.org/2001/XMLSchema#string

Yeh Ching Linn

http://www.w3.org/2001/XMLSchema#string

P2860

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape

Prospect for immunotherapy of acute lymphoblastic leukemia.

Tim-3: an emerging target in the cancer immunotherapy landscape.

Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies.

TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines.

Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation

CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1.

A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma

P2888

s00262-016-1815-8

P304

525-536

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00262-016-1815-8

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

65

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-03-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1039214763

http://www.w3.org/2001/XMLSchema#string

P698

26961084

http://www.w3.org/2001/XMLSchema#string

P921